Shanghai, China — Recently, the VitaFlow Liberty^® Transcatheter Aortic Valve and Retrievable Delivery System (referred to as "VitaFlow Liberty^®"), a new generation of transcatheter aortic valve implantation (TAVI) product self-developed by MicroPort CardioFlow Medtech Corporation (02160.HK, hereinafter referred to as " MicroPort^® CardioFlow "), has received market approval from the MEDICAL DEVICE AUTHORITY Malaysia (Authorization Number: GD5322224-178777).

As the world's only electric retrievable transcatheter aortic valve system, VitaFlow Liberty^® was approved for marketing by the NMPA in 2021 (Registration Number: NMPA 20213130655). Since then, it has been introduced to several overseas countries and, became the first domestically developed transcatheter aortic valve system to receive CE certification in the European Union this year. To date, the VitaFlow^® series TAVI solution along with its accessory - the Alwide^® series Balloon Catheter, has successfully entered over 700 leading hospitals across 13 countries and regions , treating more than 10,000 patients with aortic valve diseases globally.

As a prominent and diverse emerging industrial nation in Asia and a rapidly developing market economy, Malaysia boasts a large population base with a growing demand for innovative, high-end medical devices and services, fueled by its fast-paced economic development. The approval of VitaFlow Liberty^® in Malaysia will provide local clinicians with superior interventional treatment options for valve diseases. It will also establish a solid foundation for further expansion into overseas markets, benefiting even more patients with structural heart diseases worldwide.